| Year |
Title |
Altmetric |
| 2023
|
Dosing Variation at Initiation of Adalimumab and Etanercept and Clinical Outcomes in Juvenile Idiopathic Arthritis: A Childhood Arthritis and Rheumatology Research Alliance Registry Study.
Arthritis Care and Research.
75:410-422.
2023
|
|
| 2023
|
Trajectories of disease activity in patients with JIA in the Childhood Arthritis and Rheumatology Research Alliance Registry.
Rheumatology.
62:804-814.
2023
|
|
| 2023
|
Patient-Reported Outcomes Among Transition-Age Young Adults With Juvenile Idiopathic Arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry.
Journal of Rheumatology.
50:98-106.
2023
|
|
| 2023
|
Race, ethnicity and patient-reported outcomes in childhood-onset systemic lupus erythematosus.
Clinical and Experimental Rheumatology.
41:186-194.
2023
|
|
| 2022
|
Baseline characteristics of children with juvenile dermatomyositis enrolled in the first year of the new Childhood Arthritis and Rheumatology Research Alliance registry
2022
|
|
| 2022
|
Correction: Intraarticular steroids as DMARD-sparing agents for juvenile idiopathic arthritis flares: Analysis of the Childhood Arthritis and Rheumatology Research Alliance Registry (Pediatric Rheumatology, (2022), 20, 1, (107), 10.1186/s12969-022-00770-y)
2022
|
|
| 2022
|
First-line options for systemic juvenile idiopathic arthritis treatment: an observational study of Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans
2022
|
|
| 2022
|
Placeholder TextIntraarticular steroids as DMARD-sparing agents for juvenile idiopathic arthritis flares: Analysis of the Childhood Arthritis and Rheumatology Research Alliance Registry
2022
|
|
| 2022
|
Social determinants of health influence disease activity and functional disability in Polyarticular Juvenile Idiopathic Arthritis
2022
|
|
| 2022
|
Effectiveness and Safety of High-Dose Biologics in Juvenile Idiopathic Arthritis in the Childhood Arthritis and Rheumatology Research Alliance.
Arthritis Care and Research.
74:1770-1779.
2022
|
|
| 2022
|
Investigation of Inactive Disease States Among Patients With Juvenile Idiopathic Arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry.
ACR Open Rheumatology.
4:825-831.
2022
|
|
| 2022
|
Childhood-onset lupus nephritis in the Childhood Arthritis and Rheumatology Research Alliance Registry: Short-term kidney status and variation in care.
Arthritis Care and Research.
2022
|
|
| 2022
|
Disease Recapture Rates After Medication Discontinuation and Flare in JIA: An Observational Study within the Childhood Arthritis and Rheumatology Research Alliance Registry.
Arthritis Care and Research.
2022
|
|
| 2022
|
Psoriasis rate is increased by the exposure to TNF inhibition in children with JIA.
Annals of the Rheumatic Diseases.
2022
|
|
| 2021
|
Community poverty level influences time to first pediatric rheumatology appointment in Polyarticular Juvenile Idiopathic Arthritis
2021
|
|
| 2021
|
Down Syndrome–Associated Arthritis Cohort in the New Childhood Arthritis and Rheumatology Research Alliance Registry: Clinical Characteristics, Treatment, and Outcomes.
Arthritis Care and Research.
73:1739-1745.
2021
|
|
| 2021
|
Impact of the Season of Birth on the Development of Juvenile Idiopathic Arthritis in the United States: A Nationwide Registry-based Study.
Journal of Rheumatology.
48.
2021
|
|
| 2021
|
Patterns of etanercept use in juvenile idiopathic arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry
2021
|
|
| 2021
|
Pharmacosurveillance in Juvenile Idiopathic Arthritis.
Rheumatic Disease Clinics of North America.
47:643-653.
2021
|
|
| 2021
|
Improved Disease Course Associated With Early Initiation of Biologics in Polyarticular Juvenile Idiopathic Arthritis: Trajectory Analysis of a Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans Study.
Arthritis and Rheumatology.
73:1910-1920.
2021
|
|
| 2021
|
Optimizing the Start Time of Biologics in Polyarticular Juvenile Idiopathic Arthritis: A Comparative Effectiveness Study of Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans.
Arthritis and Rheumatology.
73:1898-1909.
2021
|
|
| 2021
|
Biologic switching among nonsystemic juvenile idiopathic arthritis patients: A cohort study in the childhood arthritis and rheumatology research alliance registry.
Journal of Rheumatology.
48:1322-1329.
2021
|
|
| 2021
|
Juvenile Spondyloarthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry: High Biologic Use, Low Prevalence of HLA–B27, and Equal Sex Representation in Sacroiliitis.
Arthritis Care and Research.
73:940-946.
2021
|
|
| 2021
|
Inflammatory bowel disease in children with systemic juvenile idiopathic arthritis.
Journal of Rheumatology.
48:567-574.
2021
|
|
| 2021
|
Making Decisions About Stopping Medicines for Well-Controlled Juvenile Idiopathic Arthritis: A Mixed-Methods Study of Patients and Caregivers.
Arthritis Care and Research.
73:374-385.
2021
|
|
| 2021
|
Oral Glucocorticoids and Incident Treatment of Diabetes Mellitus, Hypertension, and Venous Thromboembolism in Children.
American Journal of Epidemiology.
190:403-412.
2021
|
|
| 2020
|
New Medications Are Needed for Children With Juvenile Idiopathic Arthritis.
Arthritis and Rheumatology.
72:1945-1951.
2020
|
|
| 2020
|
Reply.
Arthritis and Rheumatology.
72:1040-1041.
2020
|
|
| 2020
|
Benefit of Anakinra in Treating Pediatric Secondary Hemophagocytic Lymphohistiocytosis.
Arthritis and Rheumatology.
72:326-334.
2020
|
|
| 2020
|
Patient and physician discordance of global disease assessment in juvenile dermatomyositis: Findings from the Childhood Arthritis & Rheumatology Research Alliance Legacy Registry
2020
|
|
| 2019
|
Association of Short-Term Ultraviolet Radiation Exposure and Disease Severity in Juvenile Dermatomyositis: Results From the Childhood Arthritis and Rheumatology Research Alliance Legacy Registry.
Arthritis Care and Research.
71:1600-1605.
2019
|
|
| 2019
|
Toward Accelerated Authorization and Access to New Medicines for Juvenile Idiopathic Arthritis.
Arthritis and Rheumatology.
71:1976-1984.
2019
|
|
| 2019
|
Comparison of second-line therapy in IVIg-refractory Kawasaki disease: a systematic review
2019
|
|
| 2019
|
Pain, functional disability, and their Association in Juvenile Fibromyalgia Compared to other pediatric rheumatic diseases
2019
|
|
| 2019
|
2019 American College of Rheumatology/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis–Associated Uveitis.
Arthritis Care and Research.
71:703-716.
2019
|
|
| 2019
|
2019 American College of Rheumatology/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis–Associated Uveitis.
Arthritis and Rheumatology.
71:864-877.
2019
|
|
| 2019
|
2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non-Systemic Polyarthritis, Sacroiliitis, and Enthesitis.
Arthritis and Rheumatology.
71:846-863.
2019
|
|
| 2019
|
2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non-Systemic Polyarthritis, Sacroiliitis, and Enthesitis.
Arthritis Care and Research.
71:717-734.
2019
|
|
| 2019
|
Primary Oral Presentation of Sarcoidosis in a Pediatric Patient.
Journal of oral surgery, anesthesia, and hospital dental service.
77:1180-1186.
2019
|
|
| 2019
|
Baseline Description of the Juvenile Localized Scleroderma Subgroup From the Childhood Arthritis and Rheumatology Research Alliance Legacy Registry.
ACR Open Rheumatology.
1:119-124.
2019
|
|
| 2019
|
Childhood arthritis and rheumatology research alliance consensus treatment plans for juvenile idiopathic arthritis–Associated and idiopathic chronic anterior uveitis.
Arthritis Care and Research.
71:482-491.
2019
|
|
| 2019
|
Serum S100A8/A9 and S100A12 Levels in Children With Polyarticular Forms of Juvenile Idiopathic Arthritis: Relationship to Maintenance of Clinically Inactive Disease During Anti–Tumor Necrosis Factor Therapy and Occurrence of Disease Flare After Discontinuation of Therapy.
Arthritis and Rheumatology.
71:451-459.
2019
|
|
| 2019
|
Juvenile idiopathic arthritis: An idea whose time has gone?.
Journal of Rheumatology.
46:124-126.
2019
|
|
| 2019
|
The prevalence of localised scleroderma in childhood assessed in the administrative claims data from the united states.
Journal of Scleroderma and Related Disorders.
4:77-78.
2019
|
|
| 2019
|
Ferritin to Erythrocyte Sedimentation Rate Ratio: Simple Measure to Identify Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis.
ACR Open Rheumatology.
1:345-349.
2019
|
|
| 2018
|
Clinical Characteristics and Factors Associated With Disability and Impaired Quality of Life in Children With Juvenile Systemic Sclerosis: Results From the Childhood Arthritis and Rheumatology Research Alliance Legacy Registry.
Arthritis Care and Research.
70:1806-1813.
2018
|
|
| 2018
|
Rituximab treatment for chronic steroid-dependent Henoch-Schonlein purpura: 8 cases and a review of the literature
2018
|
|
| 2018
|
Association of statin exposure with histologically confirmed idiopathic inflammatory myositis in an Australian population.
JAMA Internal Medicine.
178:1210-1222.
2018
|
|
| 2018
|
Risk factors for intraarticular heterotopic bone formation in the temporomandibular joint in Juvenile idiopathic arthritis.
Journal of Rheumatology.
45:1301-1307.
2018
|
|
| 2018
|
Risk, Timing, and Predictors of Disease Flare After Discontinuation of Anti–Tumor Necrosis Factor Therapy in Children With Polyarticular Forms of Juvenile Idiopathic Arthritis With Clinically Inactive Disease.
Arthritis and Rheumatology.
70:1508-1518.
2018
|
|
| 2018
|
Juvenile Idiopathic Arthritis: Oligoarthritis and Polyarthritis.
Pediatric Clinics of North America.
65:657-674.
2018
|
|
| 2018
|
Risk of malignancy associated with paediatric use of tumour necrosis factor inhibitors.
Annals of the Rheumatic Diseases.
77:1012-1016.
2018
|
|
| 2018
|
Subcutaneous Abatacept in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis: Results From a Phase III Open-Label Study.
Arthritis and Rheumatology.
70:1144-1154.
2018
|
|
| 2018
|
Bayesian comparative effectiveness study of four consensus treatment plans for initial management of systemic juvenile idiopathic arthritis: FiRst-Line Options for Systemic juvenile idiopathic arthritis Treatment (FROST).
Clinical Trials.
15:268-277.
2018
|
|
| 2018
|
High Levels of DEK Autoantibodies in Sera of Patients With Polyarticular Juvenile Idiopathic Arthritis and With Early Disease Flares Following Cessation of Anti–Tumor Necrosis Factor Therapy.
Arthritis and Rheumatology.
70:594-605.
2018
|
|
| 2018
|
Adiposity in juvenile psoriatic arthritis.
Journal of Rheumatology.
45:411-418.
2018
|
|
| 2018
|
Delays to Care in Pediatric Lupus Patients: Data From the Childhood Arthritis and Rheumatology Research Alliance Legacy Registry.
Arthritis Care and Research.
70:420-427.
2018
|
|
| 2018
|
Assessing the prevalence of juvenile systemic sclerosis in childhood using administrative claims data from the United States.
Journal of Scleroderma and Related Disorders.
3:189-190.
2018
|
|
| 2018
|
Comparative effectiveness of tumor necrosis factor agents and disease-modifying antirheumatic therapy in children with enthesitis-related arthritis: The first year after diagnosis.
Journal of Rheumatology.
45:107-114.
2018
|
|
| 2017
|
Evidence for updating the core domain set of outcome measures for juvenile idiopathic arthritis: Report from a special interest group at OMERACT 2016.
Journal of Rheumatology.
44:1884-1888.
2017
|
|
| 2017
|
Risk of tuberculosis among Alabama children and adolescents treated with tumor necrosis factor inhibitors: A retrospective study
2017
|
|
| 2017
|
Serious Infections in Childhood-Onset Systemic Lupus Erythematosus: Using Administrative Claims Data to Investigate Disease Outcomes.
Arthritis Care and Research.
69:1617-1619.
2017
|
|
| 2017
|
Biologic Agents in the Treatment of Childhood-Onset Rheumatic Disease.
Journal of Pediatrics.
189:31-39.
2017
|
|
| 2017
|
Changing Trends in Opioid Use Among Patients With Rheumatoid Arthritis in the United States.
Arthritis and Rheumatology.
69:1733-1740.
2017
|
|
| 2017
|
Methotrexate-induced nausea in the treatment of juvenile idiopathic arthritis
2017
|
|
| 2017
|
Multicenter inception cohort of enthesitis-related arthritis: Variation in disease characteristics and treatment approaches.
Arthritis Research and Therapy.
19.
2017
|
|
| 2017
|
Race, Income, and Disease Outcomes in Juvenile Dermatomyositis.
Journal of Pediatrics.
184:38-44.e1.
2017
|
|
| 2017
|
A survey of national and multi-national registries and cohort studies in juvenile idiopathic arthritis: Challenges and opportunities
2017
|
|
| 2017
|
The new Childhood Arthritis and Rheumatology Research Alliance (CARRA) registry: Design, rationale, and characteristics of patients enrolled in the first 12months
2017
|
|
| 2017
|
Pilot study comparing the Childhood Arthritis & Rheumatology Research Alliance (CARRA) systemic Juvenile Idiopathic Arthritis Consensus Treatment Plans
2017
|
|
| 2017
|
Attitudes and approaches for withdrawing drugs for children with clinically inactive nonsystemic JIA: A survey of the childhood arthritis and rheumatology research alliance.
Journal of Rheumatology.
44:352-360.
2017
|
|
| 2016
|
Cost-Effectiveness Analysis of First-Line Treatment With Biologic Agents in Polyarticular Juvenile Idiopathic Arthritis.
Arthritis Care and Research.
68:1803-1811.
2016
|
|
| 2016
|
Patient's experience with subcutaneous and oral methotrexate for the treatment of rheumatoid arthritis.
BMC Musculoskeletal Disorders.
17.
2016
|
|
| 2016
|
The risk of hospitalized infection following initiation of biologic agents versus methotrexate in the treatment of juvenile idiopathic arthritis.
Arthritis Research and Therapy.
18.
2016
|
|
| 2016
|
Analysis of health care claims during the peri-transfer stage of transition from pediatric to adult care among juvenile idiopathic arthritis patients
2016
|
|
| 2016
|
The systemic juvenile idiopathic arthritis cohort of the childhood arthritis and rheumatology research alliance registry: 2010-2013.
Journal of Rheumatology.
43:1755-1762.
2016
|
|
| 2016
|
A heterozygous RAB27A mutation associated with delayed cytolytic granule polarization and hemophagocytic lymphohistiocytosis.
Journal of Immunology.
196:2492-2503.
2016
|
|
| 2016
|
Familial autoimmunity in the childhood arthritis and rheumatology research alliance registry
2016
|
|
| 2016
|
Risk of nonmelanoma skin cancer associated with the use of immunosuppressant and biologic agents in patients with a history of autoimmune disease and nonmelanoma skin cancer.
JAMA Dermatology.
152:164-172.
2016
|
|
| 2016
|
Comparative Risk of Hospitalized Infection Associated with Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare.
Arthritis and Rheumatology.
68:56-66.
2016
|
|
| 2015
|
Magnetic resonance imaging findings following intraarticular infliximab therapy for refractory temporomandibular joint arthritis among children with juvenile idiopathic arthritis.
Journal of Rheumatology.
42:2155-2159.
2015
|
|
| 2015
|
Risk of hospitalised infection in rheumatoid arthritis patients receiving biologics following a previous infection while on treatment with anti-TNF therapy.
Annals of the Rheumatic Diseases.
74:1065-1071.
2015
|
|
| 2015
|
Impact of biologic agents with and without concomitant methotrexate and at reduced doses in older rheumatoid arthritis patients.
Arthritis Care and Research.
67:624-632.
2015
|
|
| 2015
|
Risks of herpes zoster in patients with rheumatoid arthritis according to biologic disease-modifying therapy.
Arthritis Care and Research.
67:731-736.
2015
|
|
| 2015
|
Novel method to collect medication adverse events in juvenile arthritis: Results from the childhood arthritis and rheumatology research alliance enhanced drug safety surveillance project.
Arthritis Care and Research.
67:529-537.
2015
|
|
| 2015
|
Safety and efficacy of rituximab in childhood-onset systemic lupus erythematosus and other rheumatic diseases.
Journal of Rheumatology.
42:541-546.
2015
|
|
| 2014
|
Development and retrospective validation of the juvenile spondyloarthritis disease activity index.
Arthritis Care and Research.
66:1775-1782.
2014
|
|
| 2014
|
Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: Results of the SAfety assessment of biologic ThERapy (SABER) study.
Annals of the Rheumatic Diseases.
73:1942-1948.
2014
|
|
| 2014
|
Use of Oral and Subcutaneous Methotrexate in Rheumatoid Arthritis Patients in the United States.
Arthritis Care and Research.
66:1604-1611.
2014
|
|
| 2014
|
Recent trends in medication usage for the treatment of juvenile idiopathic arthritis and the influence of tumor necrosis factor inhibitors.
Journal of Rheumatology.
41:2078-2084.
2014
|
|
| 2014
|
Adding canakinumab to the childhood arthritis and rheumatology research alliance consensus treatment plans for systemic juvenile idiopathic arthritis: Comment on the article by DeWitt et al.
Arthritis Care and Research.
66:1430-1431.
2014
|
|
| 2014
|
Treatment advances in systemic juvenile idiopathic arthritis.
F1000prime reports.
6.
2014
|
|
| 2014
|
Changes in body mass index in children with juvenile idiopathic arthritis treated with tumor necrosis factor inhibitors.
Journal of Rheumatology.
41:113-118.
2014
|
|
| 2014
|
Imaging of the temporomandibular joint in juvenile idiopathic arthritis.
Arthritis Care and Research.
66:47-54.
2014
|
|
| 2014
|
Risk of malignancy associated with biologic agents in pediatric rheumatic disease.
Current Opinion in Rheumatology.
26:538-542.
2014
|
|
| 2013
|
Using registries to identify adverse events in rheumatic diseases.
Pediatrics.
132.
2013
|
|
| 2013
|
2013 Update of the 2011 American College of Rheumatology Recommendations for the treatment of juvenile idiopathic arthritis: Recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications.
Arthritis and Rheumatism.
65:2499-2512.
2013
|
|
| 2013
|
2013 Update of the 2011 American college of rheumatology recommendations for the treatment of juvenile idiopathic arthritis: Recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications.
Arthritis Care and Research.
65:1551-1563.
2013
|
|
| 2013
|
High doses of infliximab in the management of juvenile idiopathic arthritis.
Journal of Rheumatology.
40:1749-1755.
2013
|
|
| 2013
|
Retinal vasculitis in two pediatric patients with systemic lupus erythematosus: A case report
2013
|
|
| 2013
|
Race, ethnicity, and disease outcomes in juvenile idiopathic arthritis: A cross-sectional analysis of the childhood arthritis and rheumatology research alliance (CARRA) registry.
Journal of Rheumatology.
40:936-942.
2013
|
|
| 2013
|
Brief report: Incidence of selected opportunistic infections among children with juvenile idiopathic arthritis.
Arthritis and Rheumatism.
65:1384-1389.
2013
|
|
| 2013
|
Infectious complications in juvenile idiopathic arthritis.
Current Rheumatology Reports.
15.
2013
|
|
| 2013
|
Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster.
Journal of the American Medical Association.
309:887-895.
2013
|
|
| 2013
|
Initiation of anti-TNF therapy and the risk of optic neuritis: From the safety assessment of biologic ThERapy (SABER) study.
American Journal of Ophthalmology.
155:183-189.e1.
2013
|
|
| 2013
|
Tumor necrosis factor α inhibitor therapy and cancer risk in chronic immune-mediated diseases.
Arthritis and Rheumatism.
65:48-58.
2013
|
|
| 2013
|
What is the background incidence of malignancy in children with rheumatic disease?.
Current Rheumatology Reports.
15.
2013
|
|
| 2012
|
Enthesitis-related arthritis is associated with higher pain intensity and poorer health status in comparison with other categories of juvenile idiopathic arthritis: The Childhood Arthritis and Rheumatology Research Alliance Registry.
Journal of Rheumatology.
39:2341-2351.
2012
|
|
| 2012
|
Improving the efficiency and effectiveness of pragmatic clinical trials in older adults in the United States.
Contemporary Clinical Trials.
33:1211-1216.
2012
|
|
| 2012
|
Use of a disease risk score to compare serious infections associated with anti-tumor necrosis factor therapy among high-versus lower-risk rheumatoid arthritis patients.
Arthritis Care and Research.
64:1480-1489.
2012
|
|
| 2012
|
Disease-modifying antirheumatic drug use in the treatment of juvenile idiopathic arthritis: A cross-sectional analysis of the CARRA registry.
Journal of Rheumatology.
39:1867-1874.
2012
|
|
| 2012
|
Risk factors for temporomandibular joint arthritis in children with juvenile idiopathic arthritis.
Journal of Rheumatology.
39:1880-1887.
2012
|
|
| 2012
|
Intra-articular corticosteroid injections to the temporomandibular joints are safe and appear to be effective therapy in children with juvenile idiopathic arthritis.
Journal of oral surgery, anesthesia, and hospital dental service.
70:1802-1807.
2012
|
|
| 2012
|
Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment.
Arthritis and Rheumatism.
64:2773-2780.
2012
|
|
| 2012
|
Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis.
Arthritis Care and Research.
64:1001-1010.
2012
|
|
| 2012
|
Back mobility and interincisor distance ranges in racially diverse North American healthy children and relationship to generalized hypermobility
2012
|
|
| 2012
|
Incidence and risk factors for progressive multifocal leukoencephalopathy among patients with selected rheumatic diseases.
Arthritis Care and Research.
64:612-615.
2012
|
|
| 2012
|
2012 update of the 2008 American college of rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis.
Arthritis Care and Research.
64:625-639.
2012
|
|
| 2012
|
Rates of malignancy associated with juvenile idiopathic arthritis and its treatment..
Arthritis and Rheumatism.
64:1263-1271.
2012
|
|
| 2011
|
Initiation of tumor necrosis factor-αantagonists and the risk of hospitalization for infection in patients with autoimmune diseases.
Journal of the American Medical Association.
306:2331-2339.
2011
|
|
| 2011
|
Attainment of inactive disease status following initiation of TNF-α inhibitor therapy for juvenile idiopathic arthritis: Enthesitis-related arthritis predicts persistent active disease.
Journal of Rheumatology.
38:2675-2681.
2011
|
|
| 2011
|
Study design for a comprehensive assessment of biologic safety using multiple healthcare data systems.
Pharmacoepidemiology and Drug Safety.
20:1199-1209.
2011
|
|
| 2011
|
Type 1 hyperlipoproteinemia and recurrent acute pancreatitis due to lipoprotein lipase antibody in a young girl with Sjögren's syndrome.
Journal of Clinical Endocrinology and Metabolism.
96:3302-3307.
2011
|
|
| 2011
|
Temporomandibular joint arthritis in pediatric Sjögren disease and sarcoidosis.
Journal of Rheumatology.
38:2272-2273.
2011
|
|
| 2011
|
Geographic distribution of endemic fungal infections among older persons, United States
2011
|
|
| 2011
|
Reply.
Arthritis Care and Research.
63:1355.
2011
|
|
| 2011
|
Reply.
Arthritis Care and Research.
63:1353.
2011
|
|
| 2011
|
High prevalence of myositis in a southeastern United States pediatric systemic lupus erythematosus cohort
2011
|
|
| 2011
|
The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents.
Annals of the Rheumatic Diseases.
70:1401-1406.
2011
|
|
| 2011
|
2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features..
Arthritis Care and Research.
63:465-482.
2011
|
|
| 2011
|
Combination therapy of abatacept and in children with refractory systemic juvenile idiopathic arthritis: A retrospective case series.
Journal of Rheumatology.
38:180-181.
2011
|
|
| 2011
|
Measuring process of arthritis care: A proposed set of quality measures for the process of care in juvenile idiopathic arthritis.
Arthritis Care and Research.
63:10-16.
2011
|
|
| 2010
|
Cost-effectiveness of multifaceted evidence implementation programs for the prevention of glucocorticoid-induced osteoporosis.
Osteoporosis International.
21:1573-1584.
2010
|
|
| 2010
|
Guilt by association - what is the true risk of malignancy in children treated with etanercept for JIA?
2010
|
|
| 2010
|
Prolonged expression of CD154 on CD4 T cells from pediatric lupus patients correlates with increased CD154 transcription, increased nuclear factor of activated T cell activity, and glomerulonephritis.
Arthritis and Rheumatism.
62:2499-2509.
2010
|
|
| 2010
|
Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide.
Annals of the Rheumatic Diseases.
69:43-47.
2010
|
|
| 2009
|
Rituximab Therapy for Severe Refractory Chronic Henoch-Schönlein Purpura.
Journal of Pediatrics.
155:136-139.
2009
|
|
| 2008
|
Optimal treatment of knee monarthritis in juvenile idiopathic arthritis: A decision analysis.
Arthritis and Rheumatism.
59:1580-1588.
2008
|
|
| 2008
|
Usage of intra-articular corticosteroid injections for the treatment of juvenile idiopathic arthritis: A survey of pediatric rheumatologists in the United States and Canada.
Clinical and Experimental Rheumatology.
26:700-703.
2008
|
|
| 2008
|
Evaluation of the presentation of systemic onset juvenile rheumatoid arthritis: Data from the Pennsylvania Systemic Onset Juvenile Arthritis Registry (PASOJAR).
Journal of Rheumatology.
35:343-348.
2008
|
|
| 2007
|
Variation in the initial treatment of knee monoarthritis in juvenile idiopathic arthritis: A survey of pediatric rheumatologists in the United States and Canada.
Journal of Rheumatology.
34:1918-1924.
2007
|
|
| 2007
|
Benefit of fluoroscopically guided intraarticular, long-acting corticosteroid injection for subtalar arthritis in juvenile idiopathic arthritis
2007
|
|
| 2007
|
Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis.
Journal of Rheumatology.
34:1133-1138.
2007
|
|
| 2007
|
Juvenile idiopathic arthritis classification criteria: Loopholes and diagnosis software [3].
Journal of Rheumatology.
34:234.
2007
|
|
| 2006
|
Benefit of intraarticular corticosteroid injection under fluoroscopic guidance for subtalar arthritis in juvenile idiopathic arthritis.
Journal of Rheumatology.
33:2330-2336.
2006
|
|
